Why and how should children be protected from the deluge of vaping related media and marketing overexposure?
- PMID: 38125806
- PMCID: PMC10729810
- DOI: 10.1183/20734735.0141-2023
Why and how should children be protected from the deluge of vaping related media and marketing overexposure?
Abstract
E-cigarettes are products delivering nicotine via inhalation and are devised to mimic tobacco smoking. While they were initially introduced as a device putatively to aid with smoking cessation, their use is now far broader than that. Use by children is significantly increasing. There is growing evidence of the potential harms of vaping. E-liquids used for e-cigarettes contain a wide range of harmful substances, and the clinical consequences of this are now being increasingly demonstrated, such as the rise in cases of e-cigarette- or vaping-associated lung injury. In addition, early use may result in long-term nicotine addiction. Vaping companies utilise marketing methods that distinctly target young people, and weak legislation in the UK allows them free rein to expose children to vaping. In this review we demonstrate why children must be protected from vaping. We must have stringent legislation to prevent easy access to e-cigarettes, including banning the convenience and affordability disposable vapes provide, and prevent marketing that does not warn about the potential health effects. The Australia approach of prescription or pharmacy only access for smoking cessation should be considered to limit exposure of children and minimise use by nonsmokers.
Copyright ©ERS 2023.
Conflict of interest statement
Conflict of interest: A.R. Smyth reports research grants (paid to the University of Nottingham) from Vertex Pharmaceuticals (outside of the current work). Payment (to University of Nottingham) for attendance by A.R. Smyth at a Viatris advisory board. Patents issued (Camara M, Williams P, Barrett D, Halliday N, Knox A, Smyth A, Fogarty A, Barr H, Forrester D. Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof, US-2016131648-A1, https://pubchem.ncbi.nlm.nih.gov/patent/US-2016131648-A1) (outside of the current work). A.R. Smyth also reports participation on a Data Safety Monitoring Board for the North American Cystic Fibrosis Foundation Therapeutics Development Network (outside of the current work). J.M. Bhatt is a PI on studies sponsored by AstraZeneca and Boehringer Ingelheim; he has no personal (financial) interests in any pharmaceutical companies. J.M. Bhatt is a current member of the Breathe editorial board. The remaining authors have nothing to disclose.
Figures
Comment in
-
Diagnosing and managing pleural disease.Breathe (Sheff). 2023 Dec;19(4):230230. doi: 10.1183/20734735.0230-2023. Epub 2023 Dec 19. Breathe (Sheff). 2023. PMID: 38127543 Free PMC article.
References
-
- Public Health England . Nicotine vaping in England: 2022 evidence update main findings. Date last accessed: 20 July 2023. Date last updated: 29 September 2022. www.gov.uk/government/publications/nicotine-vaping-in-england-2022-evide...
-
- Department of Health and Social Care . No more free vapes for kids. Date last accessed: 20 July 2023. Date last updated: 31 May 2023. www.gov.uk/government/news/no-more-free-vapes-for-kids
Publication types
LinkOut - more resources
Full Text Sources